Hemedex, Inc. Presents Data and Corporate Vision at Emerging Medical Technologies - East Conferences
CAMBRIDGE, Mass., Sept. 11 /PRNewswire/ -- Hemedex, Inc., a privately held company developing a stream of products to provide clinicians with valuable new prognostic data by measuring tissue blood flow in multiple clinical application areas, presented an overview of recent milestones achieved by the Company, and outlined management's vision for near term development and future strategic growth, to healthcare industry executives and investors at the recently held EMT-East Conference.
Gregory T. Martin, Ph.D., Hemedex Vice President of Research and Development, described the evolution of the Company's proprietary technology, and detailed the significant near term development milestones achieved, including the successful completion of clinical studies involving over 200 neurosurgical and organ transplantation patients. Dr. Martin stated: "The measurements made by the Company's technology are a long sought after and important parameter in understanding and managing critical medical situations, and prior to the development of our technology, the capability to get continuous, real time, perfusion measurements in absolute units did not exist".
Further, he said that the Company's successful clinical studies in neurosurgery and organ transplantation will continue at the existing sites in Europe and Asia, and that new, expanded studies are slated to begin in Q4 2001 at multiple, major medical centers in the U.S. These new clinical studies will focus not only on neurosurgery and organ transplantation, but also include indications such as plastic and reconstructive surgery, cardiovascular and vascular surgery, oncology, and shock monitoring, among others.
Additionally, the Company will be submitting its first 510(k) application to the FDA in Q4 2001, and is currently in the process of ramping up its manufacturing capabilities to meet the expected demand for its perfusion monitoring devices.
Dr. Martin released data from both pre-clinical and clinical applications of the Company's proprietary thermal diffusion technology, which served to further validate the Company's claims of achieving real-time, minimally invasive, accurate perfusion measurements, in absolute units, and in multiple, diverse, medical and surgical indications. As explained by Dr. Martin, the Company expects worldwide sales of its proprietary perfusion monitoring technology to begin in early 2002. He described the Company's first strategic partnership, which is a distribution agreement covering defined indications in specific Asian markets, and explained that the Company's intent is to form additional strategic alliances with other healthcare companies that have synergistic technologies, or dominant market share and critical mass in target markets.
[ TOP ]